Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mannkind Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Julius Wong who wrote (4)

9/25/2014 1:02:29 PM

From: Savant

Respond to of 84

Mannkind announced closing of global licensing agreement with Sanofi (SNY); will receive a $150 mln upfront payment within ten days of the closing

Co announced the closing of a worldwide exclusive collaboration and licensing agreement with Sanofi for development and commercialization of Afrezza Inhalation Powder. The closing follows completion of the US Federal Trade Commission's review of the transaction under the Hart-Scott-Rodino Act and the completion of documentation related to the $175 million loan facility being provided to MannKind by an affiliate of Sanofi in connection with the collaboration and license agreement. Under the terms of the collaboration and license agreement, MannKind will receive a $150 million upfront payment within ten days of the closing.